Please assess the completion status of the following clinical trial:

Trial Title: A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* The duration of the index hospitalization must have been at least 3 and no more than 10 consecutive days~* Must meet venous thromboembolism (VTE) risk criteria with a total modified Improve VTE Risk Score of: greater than or equal 4, or 3 with D-dimer \> 2\* upper limit of normal (ULN), or 2 with D-dimer \> 2\*ULN~Key Exclusion Criteria:~* Any serious bleeding within 3 months prior to randomization or occurring during index hospitalization~* Serious trauma (including head trauma) within 4 weeks before randomization~* History of hemorrhagic stroke at any time in the past~* Any medical condition that requires chronic use of any parenteral or oral anticoagulation

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban (Type: EXPERIMENTAL): Each patient will receive either 10 mg or 7.5 mg rivaroxaban tablet once daily orally (by mouth) for 45 days. The dosing will depend on a creatinine clearance at screening.
- Placebo (Type: PLACEBO_COMPARATOR): Each patient will receive matching placebo tablet once daily orally (by mouth) for 45 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).